[1] Bray F, Ferlay J, Soerjomataram I, et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.   doi: 10.3322/caac.21492
[2] Zhu Y, Fu L, Jing W, et al.  The value of magnetic resonance imaging in esophageal carcinoma: tool or toy?[J]. Asia Pac J Clin Oncol, 2019, 15(3): 101-107.   doi: 10.1111/ajco.13112
[3] Guo J, Wang ZQ, Qin JJ, et al.  A prospective analysis of the diagnostic accuracy of 3T MRI, CT and endoscopic ultrasound for preoperative T staging of potentially resectable esophageal cancer[J]. Cancer Imaging, 2020, 20(1): 64-.   doi: 10.1186/s40644-020-00343-w
[4] 于军, 张莺, 任东栋, 等.  18F-FDG PET/CT与PET/MRI在结直肠癌肝转移诊断中的比较分析[J]. 国际放射医学核医学杂志, 2021, 45(2): 75-82.   doi: 10.3760/cma.j.cn121381-202003009-00013
Yu J, Zhang Y, Ren DD, et al.  Comparative analysis of 18F-FDG PET/CT and PET/MRI in the diagnosis of colorectal cancer liver metastases[J]. Int J Radiat Med Nucl Med, 2021, 45(2): 75-82.   doi: 10.3760/cma.j.cn121381-202003009-00013
[5] Martin O, Schaarschmidt BM, Kirchner J, et al.  PET/MRI versus PET/CT for whole-body staging: results from a single-center observational study on 1, 003 sequential examinations[J]. J Nucl Med, 2020, 61(8): 1131-1136.   doi: 10.2967/jnumed.119.233940
[6] Morsing A, Hildebrandt MG, Vilstrup MH, et al.  Hybrid PET/MRI in major cancers: a scoping review[J]. Eur J Nucl Med Mol Imaging, 2019, 46(10): 2138-2151.   doi: 10.1007/s00259-019-04402-8
[7] Haubold J, Demircioglu A, Gratz M, et al.  Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric 18F-FET PET-MRI and MR fingerprinting[J]. Eur J Nucl Med Mol Imaging, 2020, 47(6): 1435-1445.   doi: 10.1007/s00259-019-04602-2
[8] Evangelista L, Zattoni F, Cassarino G, et al.  PET/MRI in prostate cancer: a systematic review and meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2021, 48(3): 859-873.   doi: 10.1007/s00259-020-05025-0
[9] Rice TW, Patil DT, Blackstone EH.  8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice[J]. Ann Cardiothorac Surg, 2017, 6(2): 119-130.   doi: 10.21037/acs.2017.03.14
[10] Lee G, Hoseok I, Kim SJ, et al.  Clinical implication of PET/MR imaging in preoperative esophageal cancer staging: comparison with PET/CT, endoscopic ultrasonography, and CT[J]. J Nucl Med, 2014, 55(8): 1242-1247.   doi: 10.2967/jnumed.114.138974
[11] Yamada I, Miyasaka N, Hikishima K, et al.  Ultra-high-resolution MR imaging of esophageal carcinoma at ultra-high field strength (7.0T) ex vivo: correlation with histopathologic findings[J]. Magn Reson Imaging, 2015, 33(4): 413-419.   doi: 10.1016/j.mri.2014.11.005
[12]

Wei Y, Wu S, Shi DP, et al. Oesophageal carcinoma: comparison of ex vivo high-resolution 3.0T MR imaging with histopathological findings[J/OL]. Sci Rep, 2016, 6: 35109[2021-02-21]. https://www.nature.com/articles/srep35109. DOI: 10.1038/srep35109.
[13] Giganti F, Ambrosi A, Petrone MC, et al.  Prospective comparison of MR with diffusion-weighted imaging, endoscopic ultrasound, MDCT and positron emission tomography-CT in the pre-operative staging of oesophageal cancer: results from a pilot study[J]. Br J Radiol, 2016, 89(1068): 20160087-.   doi: 10.1259/bjr.20160087
[14] Yu CW, Chen XJ, Lin YH, et al.  Prognostic value of 18F-FDG PET/MR imaging biomarkers in oesophageal squamous cell carcinoma[J]. Eur J Radiol, 2019, 120: 108671-.   doi: 10.1016/j.ejrad.2019.108671